3 recruiting, 2 completed, 2 not yet recruiting, 1 suspended. 8 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 3, Completed 2, Not yet recruiting 2, Suspended 1 |
| Phase 1 | 4 | Recruiting 2, Completed 1, Suspended 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Myelofibrosis (MF): new trials by email Literature Review of Myelofibrosis (MF) trials Research Report on Myelofibrosis (MF)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis Luspatercept, Control - Luspatercept, Poor Erythroid Engraftment | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 196 | 2026-05-01 | 2026-04-20 |
| Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis Gecacitinib (also known as Jaktinib) - Myelofibrosis (MF), HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 39 | 2026-03-16 | 2026-03-13 |
| Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) Axatilimab (SNDX-6352), Ruxolitinib - Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML) | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 66 | 2026-01-02 | 2026-10-09 |
| A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors Roginolisib - Myelofibrosis (MF) | Phase 1 / Phase 2 | Recruiting | iOnctura | 26 | 2025-11-17 | 2026-06-23 |
| MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial Methotrexate (MTX) - Polycythemia Vera (PV), Essential Thrombocythemia (ET) | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 54 | 2024-10-02 | 2025-12-17 |
| A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis Ruxolitinib, Navitoclax - Myelofibrosis (MF) | Phase 2 | Completed | AbbVie | 191 | 2017-10-31 | 2026-01-20 |
| Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) KB004, Monoclonal Antibody - Myelodysplastic Syndrome (MDS), Myelofibrosis (MF) | Phase 1 / Phase 2 | Suspended | Humanigen, Inc. | 120 | 2010-09-01 | 2015-11-17 |
| Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders Chinese herbal concoction twice a day for 6 months - Myelodysplastic Syndrome (MDS), Aplastic Anaemia (AA) | Phase 1 / Phase 2 | Completed | Singapore General Hospital | 38 | 2009-07-01 | 2017-02-10 |
Primary Myelofibrosis (8) · Myelodysplastic Syndromes (2) · Anemia, Aplastic (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Myelomonocytic, Chronic (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Polycythemia Vera (1) · Splenomegaly (1) · Thrombocythemia, Essential (1) · beta-Thalassemia (1)
Bone Marrow Diseases (8) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Myeloproliferative Disorders (7) · Neoplasms (3) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Pathological Conditions, Signs and Symptoms (2) · Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Bone Marrow Failure Disorders (1) · Bone Marrow Neoplasms (1)
ruxolitinib (2) · KB004 (1) · Methotrexate (1) · axatilimab (1) · luspatercept (1) · navitoclax (1)
AbbVie (1) · Humanigen, Inc. (1) · Icahn School of Medicine at Mount Sinai (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · M.D. Anderson Cancer Center (1) · Nanfang Hospital, Southern Medical University (1) · Singapore General Hospital (1) · iOnctura (1)
United States (4) · Australia (2) · Italy (2) · Spain (2) · United Kingdom (2) · Canada (1) · China (1) · Croatia (1) · Greece (1) · Hungary (1) · Israel (1) · Japan (1) · Puerto Rico (1) · Singapore (1) · South Korea (1)
John Mascarenhas (1) · Michael Lahn, Dr (1) · Morgan Lam (1) · Naveen Pemmaraju, MD (1) · Qifa Liu (1)
PMID 20424252, PMID 21742281, PMID 27736729, PMID 28096091, PMID 29895954, PMID 34002031, PMID 35180010, PMID 35576960, PMID 37311468, PMID 40454409, PMID 41846295, PMID 42842696
2017 (1)